Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Ono Pharmaceutical
Pharma
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
Ono will buy Deciphera for $2.4 billion. Novartis invests further in radiotherapy with two deals. WuXi Biologics has withdrawn from the BIO 2024.
Angus Liu
May 3, 2024 7:20am
Opdivo maker Ono pays $2.4B for Deciphera
Apr 29, 2024 8:55am
Takeda, WuXi, LianBio—Fierce Pharma Asia
Feb 16, 2024 8:24am
FDA oncology chief, Senate bill, Insilico—Fierce Pharma Asia
Apr 1, 2022 9:35am
AZ faces Ono patent infringement suit on Imfinzi
Mar 1, 2022 9:10am
BMS, Bayer team up on colorectal cancer combo
Jul 18, 2019 11:57am
